Simultaneous quantification of imatinib and its main metabolite N-demethyl-imatinib in human plasma by liquid chromatography-tandem mass spectrometry and its application to therapeutic drug monitoring in patients with gastrointestinal stromal tumor.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Biomedical chromotography

• Publication date

  2017-12-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/bmc.4022PMID 28621487
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Imatinib Pharmacokinetics in a Large Observational Cohort of Gastrointestinal Stromal Tumour Patients

  2017cited by this paper
• Relationship between imatinib trough concentration and outcomes in the treatment of advanced gastrointestinal stromal tumours in a real-life setting.

  2016cited by this paper
• Simultaneous quantification of imatinib and CGP74588 in human plasma by liquid chromatography-time of flight mass spectrometry (LC-TOF-MS)

  2016cited by this paper
• In Vivo Cytochrome P450 3A Isoenzyme Activity and Pharmacokinetics of Imatinib in Relation to Therapeutic Outcome in Patients With Chronic Myeloid Leukemia

  2016cited by this paper
• Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC-UV or LC-MS/MS methods.

  2016cited by this paper
• On-cartridge derivatization coupled with solid-phase extraction for the ultra-sensitive determination of minodronic acid in human plasma by LC-MS/MS method.

  2015cited by this paper
• Drug safety evaluation of sorafenib for treatment of solid tumors: consequences for the risk assessment and management of cancer patients

  2014cited by this paper
• Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers.

  2014cited by this paper
• LC-MS-MS determination of imatinib and N-desmethyl imatinib in human plasma.

  2014cited by this paper
• The kinetic deuterium isotope effect as applied to metabolic deactivation of imatinib to the des-methyl metabolite, CGP74588.

  2013cited by this paper
• The European Bioanalysis Forum community's evaluation, interpretation and implementation of the European Medicines Agency guideline on Bioanalytical Method Validation.

  2013cited by this paper
• A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometry.

  2013cited by this paper
• Determination of imatinib and its active metabolite N-desmethyl imatinib in human plasma by liquid chromatography/tandem mass spectrometry

  2012influential reference
• Method development and validation for the simultaneous determination of imatinib mesylate and N-desmethyl imatinib using rapid resolution high performance liquid chromatography coupled with UV-detection.

  2011cited by this paper
• Optimization of the simultaneous determination of imatinib and its major metabolite, CGP74588, in human plasma by a rapid HPLC method using D-optimal experimental design.

  2011cited by this paper
• Clinical Pharmacokinetics of Tyrosine Kinase Inhibitors

  2011cited by this paper
• Use of Total and Unbound Imatinib and Metabolite LC-MS/MS Assay to Understand Individual Responses in CML and GIST Patients

  2011influential reference
• Participation of CYP2C8 and CYP3A4 in the N‐demethylation of imatinib in human hepatic microsomes

  2010cited by this paper
• Simultaneous determination of nilotinib, imatinib and its main metabolite (CGP-74588) in human plasma by ultra-violet high performance liquid chromatography.

  2010cited by this paper
• Cross-sectional study of imatinib plasma trough levels in patients with advanced gastrointestinal stromal tumors: impact of gastrointestinal resection on exposure to imatinib.

  2010cited by this paper
• Clinical pharmacokinetics of tyrosine kinase inhibitors.

  2009cited by this paper
• Imatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumors.

  2009cited by this paper
• Imatinib metabolite profiling in parallel to imatinib quantification in plasma of treated patients using liquid chromatography-mass spectrometry.

  2008influential reference
• Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study.

  2008cited by this paper
• Rapid and simultaneous determination of nifedipine and dehydronifedipine in human plasma by liquid chromatography-tandem mass spectrometry: Application to a clinical herb-drug interaction study.

  2007cited by this paper
• Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia.

  2007cited by this paper
• Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography.

  2007cited by this paper
• Liquid Chromatography‐Electrospray Mass Spectrometry Determination of Imatinib and Its Main Metabolite, N‐Desmethyl‐Imatinib in Human Plasma

  2006influential reference
• Population pharmacokinetics of imatinib and the role of alpha-acid glycoprotein.

  2006cited by this paper
• METABOLISM AND DISPOSITION OF IMATINIB MESYLATE IN HEALTHY VOLUNTEERS

  2005influential reference
• Clinical Pharmacokinetics of Imatinib

  2005influential reference
• Population pharmacokinetics of imatinib mesylate in patients with chronic-phase chronic myeloid leukaemia: results of a phase III study.

  2005cited by this paper
• P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate

  2004cited by this paper
• Determination of imatinib (Gleevec) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection.

  2004cited by this paper
• Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588

  2004cited by this paper
• Liquid chromatographic method for detection and quantitation of STI-571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations.

  2004cited by this paper
• Active transport of imatinib into and out of cells: implications for drug resistance.

  2004cited by this paper
• Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients.

  2004cited by this paper
• Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples.

  2004cited by this paper
• Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS.

  2003cited by this paper
• Liquid chromatography/tandem mass spectrometry methods for quantitation of mevalonic acid in human plasma and urine: method validation, demonstration of using a surrogate analyte, and demonstration of unacceptable matrix effect in spite of use of a stable isotope analog internal standard.

  2003cited by this paper
• Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma.

  2003influential reference
• High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.

  2002cited by this paper

• ETV1 genetic polymorphisms as a candidate prognosis biomarker of Gastrointestinal stromal tumor

  2025cites this paper
• Development and application of a novel method for the determination of imatinib and N-desmethylimatinib in plasma based on molecularly imprinted sorbent in a solid-phase extraction process combined with liquid chromatography mass spectrometry detection

  2025cites this paper
• Genetic and pharmacokinetic factors associated with imatinib-induced toxicities in gastrointestinal stromal tumors

  2025cites this paper
• MonoTip C18 pipette tip solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry enables rapid and automated therapeutic drug monitoring of tyrosine kinase inhibitors

  2024cites this paper
• Pretreatment and analysis techniques development of TKIs in biological samples for pharmacokinetic studies and therapeutic drug monitoring

  2023cites this paper
• Therapeutic Drug Monitoring of Imatinib and N‐Desmethyl Imatinib in Chronic Myeloid Leukemia Patients Using LC‐MS/MS in a Cohort Study

  2023cites this paper
• Development and clinical application of a liquid chromatography-tandem mass spectrometry-based assay to quantify eight tyrosine kinase inhibitors in human plasma

  2023cites this paper
• A nanoemulsion-based delivery system for imatinib and in vitro anticancer efficacy

  2021cites this paper
• Individualized Management of Blood Concentration in Patients with Gastrointestinal Stromal Tumors

  2021cites this paper
• Interpretation of MS–MS spectra of small-molecule signal transduction inhibitors using accurate-m/z data and m/z-shifts with stable-isotope-labeled analogues and metabolites

  2021cites this paper
• Sensitive Determination of Imatinib Mesylate in Human Plasma Using DABCO-Based Ionic Liquid-Modified Magnetic Nanoparticles

  2020cites this paper
• HPLC methods for quantifying anticancer drugs in human samples: A systematic review.

  2020cites this paper
• OTT_A_279998 13345..13355

  2020cites this paper
• Quantification of imatinib and related compounds using capillary electrophoresis‐tandem mass spectrometry with field‐amplified sample stacking

  2020cites this paper
• UPLC‐MS/MS method for the simultaneous determination of imatinib, voriconazole and their metabolites concentrations in rat plasma

  2019cites this paper
• Chitosan grafted onto Fe3O4@poly(N-vinylcaprolactam) as a new sorbent for detecting Imatinib mesylate in biosamples using UPLC-MS/MS.

  2019cites this paper
• Can therapeutic drug monitoring increase the safety of Imatinib in GIST patients?

  2018cites this paper